Oricell Therapeutics

Based in Shanghai, China and founded in 2015, Oricell Therapeutics Co. , Ltd. , trading as Oricell Therapeutics, is a biotech company that focuses on the research and development of tumor immune cell therapy products. The company was formerly the research and development center of The Origincell Technology Group.

The company has established subsidiaries in Hong Kong and the United States. In April 2026, Oricell Therapeutics raised USD 110 million in Pre-IPO funding co-led by Vivo Capital, Shunxi Fund, Qiming Venture Partners and an unspecified investor, with participation from Sovereign Wealth Funds, Shandong High-tech Investment Corporation, Ruifeng Capital, E-Town International Industrial Investment, NGS Super, Elikon Venture and other investors. The company's main product pipeline includes autologous CAR-T immunotherapy products for the treatment of advanced hepatocellular carcinoma, relapsed refractory multiple myeloma and other novel drugs for tumor immunotherapy. The company's products are used in diseases such as liver cancer, ovarian cancer, gastric cancer and cervical cancer.

The company generates revenue from developing cell therapies leveraging CAR-T technology. The Pre-IPO funding raised in April 2026 will primarily be used to accelerate the company's internationalization strategy, promote the global multi-center clinical development of its core pipeline, further solidify its technological barriers in the cell therapy field, accelerate the value release of its industrialization pipeline, and fully prepare for upcoming capital market milestones.